Hepatotoxicity is the risk factor with gemtuzumab ozogamicin treatment in acute myelogenous leukaemia patients

Sayed Aliul Hasan Abdi1, Shatrunajay Shukla2, Jasim Khan3

  • 1Department of Medical Elementology & Toxicology, Jamia Hamdard (Hamdard University), New Delhi, India; Department of Pharmacology, Jamia Hamdard (Hamdard University), New Delhi, India; Department of Pharmacy, Al Baha University, Kingdom of Saudi Arabia.

Abstract

No abstract available in PubMed .